Drug intelligence / Profile preview

nivolumab + ipilimumab + sirolimus + prednisone

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

This combination therapy consists of two immune checkpoint inhibitors, nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4), administered alongside the immunosuppressants sirolimus (mTOR inhibitor) and prednisone (glucocorticoid receptor agonist). This specific regimen is being investigated by the National Cancer Institute (NCI) in a Phase 2 clinical trial (NCT05896839) specifically for kidney transplant recipients who have developed unresectable or metastatic cutaneous cancers, such as melanoma, Merkel cell carcinoma, basal cell carcinoma, and cutaneous squamous cell carcinoma. The rationale is to leverage the anti-tumor activity of the checkpoint inhibitors while using sirolimus and prednisone to prevent rejection of the transplanted kidney, a common complication when transplant patients receive immunotherapy.

Brand names: OpdivoYervoyRapamuneRayos
Other names: Nivolumab and Ipilimumab with Sirolimus and Prednisone

Targets

GR (Glucocorticoid receptor)PDCD1 (Programmed cell death protein 1 receptor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)mTOR (Mammalian target of rapamycin kinase)

Beyond the preview

Go deeper on nivolumab + ipilimumab + sirolimus + prednisone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nivolumab + ipilimumab + sirolimus + prednisone.

Explore the full profile